AI Consensus Investment Thesis
Hims & Hers Health (HIMS) Stock Forecast and AI Rating
Forecast targets and rating
Final recommendation
Open Short Position
For hedged portfolios, this is the short-side candidate.
1-Year
SELL ALL$23
-23.5%5-Year
PARTIALLY SELL$29
-6.4%Latest flagship insight
How Regulatory Shifts and Margin Compression Are Reshaping Digital Healthcare Platforms
There is high consensus that the platform faces severe structural headwinds as regulatory loopholes close. While international acquisitions temporarily mask organic deceleration, the forced transition from high-margin compounded treatments to low-margin branded distribution permanently impairs unit economics, escalating customer acquisition costs and leverage under restrictive monetary conditions.
This is the latest published deep-analysis batch. Audit previous forecasts in full transparency
Warren Buffett (Value Purist), Superintelligence (Anthropologist), Ray Dalio (Strategist), Machiavelli (Insider), Elon Musk (Visionary), Michael Burry (Vulture), J.P. Morgan (Titan), Sherlock Holmes (Whistleblower). Some archetypes run in multiple modes, resulting in 12 advisors total.
Research support only. We don't give financial advice.
Gemini
Claude
ChatGPT
GrokExecutive Summary
Dotted terms open concise definitions. Browse technical terms
Interactive forecast chart
The base-case narrative indicates a painful structural transition from a high-margin regulatory arbitrageregulatory arbitrageUsing differences among rules, jurisdictions, or legal classifications to reduce regulatory burden or gain economic advantage.View full glossary entry model to a commoditized digital pharmacy. The closure of the compounded GLP-1glp 1Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, insulin response, digestion, and appetite.View full glossary entry shortage loophole forces a pivot to low-margin branded distribution, permanently compressing gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry. Concurrently, rising customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry and heavy debt-funded international acquisitions introduce severe balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry fragility under a restrictive monetary regimemonetary regimeThe prevailing framework of central-bank policy, interest rates, money creation, and exchange-rate management.View full glossary entry. While legacy verticals offer a stable cash-flow floor, they are insufficient to sustain historical growth multiplesgrowth multipleGrowth multiple is a valuation premium assigned to businesses expected to sustain faster expansion than peers or the broader market.View full glossary entry.
Key insights
- The termination of the FDA compounding loophole permanently impairs the high-margin weight-loss growth engine, forcing a transition to branded alternatives.
- Transitioning to branded distribution shifts the business model toward a low-margin, capital-intensive retail pharmacy profile with structurally lower return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry.
- Customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry are escalating due to search engine disintermediation, AI-driven search agents, and intense competitive density from deep-pocketed players.
- Elevated leverage from recent international acquisitions and convertible debtconvertible debtDebt instruments convertible into equity, impacting balance sheet risk and potential shareholder dilution.View full glossary entry issuance increases refinancing risks in a higher-for-longer interest rate environment.
- Legacy wellness verticals in hair loss and erectile dysfunction provide a stable cash-flow floor but cannot offset broader margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry.
- Sophisticated investors should monitor customer lifetime value to customer acquisition costcustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry ratios and cash conversion cycles for signs of operational stabilization.
Deep Dive
Alpha Gap & Repricing Catalysts
Where does the current market narrative diverge from our AI Forecasts—and what could close the gap?
Market Narrative
What does the market currently expect? The conventional market narrative remains highly optimistic, anchoring to the explosive revenue growth and profitability achieved during the 2024-2025 period. The crowd views the platform as a secular technology-enabled healthcare disruptor that will permanently dominate the weight-loss market. Media and sell-side analysts largely celebrate recent partnerships with major pharmaceutical manufacturers as strategic victories that eliminate regulatory risks while securing supply. They tend to treat the recent margin compressionmargin compressionThe narrowing of profit margins due to rising costs or declining pricing power.View full glossary entry, net losses, and rising debt levels as temporary transition costs or necessary infrastructure investments, expecting hyper-growth to continue indefinitely.
Alpha Gap
What is the biggest difference between market expectations and our AI forecasts? The core information gap lies in the misclassification of the company's business model and unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry. While the crowd prices the asset as a high-margin technology platform, it is structurally a marketing-heavy digital pharmacy that capitalized on a temporary regulatory loophole. The transition from compounding custom formulations to distributing patented, branded drugs permanently destroys gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, shifting them from software-like levels to low-margin retail pharmacy economics. Furthermore, the market underappreciates the impact of search engine disintermediation and impending regulatory crackdowns on subscription cancellation practices. These factors will structurally accelerate customer churn and inflate acquisition costs, proving that past hyper-growth was a cyclical subsidy rather than a durable competitive moateconomic moatCompetitive advantage protecting market share and profitability from rivals.View full glossary entry.
Repricing Catalyst
What could make the market recognize and close that gap? The primary convergence catalyst will be the upcoming earnings releases over the next two to three quarters. These financial disclosures will fully reflect the margin collapse from the branded drug distribution transition and the heavy integration costs of recent international acquisitions. Once the market observes structurally lower gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry, negative free cash flownegative free cash flowA condition where cash outflows for operations and investment exceed cash generated in the period.View full glossary entry, and elevated interest expenses, the growth-tech narrative will become untenable. Additionally, the formal resolution of branded drug shortages by regulators will legally halt remaining compounding operations, forcing a rapid multiple compressionmultiple compressionA decline in valuation ratios such as price-to-earnings or enterprise-value-to-sales.View full glossary entry toward traditional retail pharmacy valuations.
Sentiment and Timing
What do sentiment, volatility, and the market-recognition cycle suggest about the thesis timing?
- Greed / Fear
- Mixed
- Volatility
- High Erratic
- Cycle position
- Reversal
While there is strong consensus regarding high expected volatility, opinions on the sentiment regime diverge. Some perspectives highlight lingering greed and momentum-driven optimism among retail investors, while others point to growing fear and capitulation as institutional capitalinstitutional capitalCapital managed by professional institutions such as pension funds, insurers, sovereign funds, endowments, or asset managers.View full glossary entry reacts to deteriorating margins and rising leverage.
Macro Regime Fit
Does the current market environment support the thesis? The macroeconomic backdrop is a severe headwind for this asset. A restrictive monetary policy regime characterized by higher-for-longer interest rates and tightening liquidity heavily penalizes highly leveraged, cash-burning growth equities. Concurrently, persistent stagflationary pressuresstagflationary pressuresEconomic pressures created when weak growth and persistent inflation occur together.View full glossary entry and rising energy costs squeeze discretionary consumer spending. Because the platform operates primarily on an out-of-pocket, cash-pay subscription model rather than insurance reimbursement, its services are highly elastic. As household budgets tighten, subscription wellness treatments face elevated churn, directly undermining the company's recurring revenuerecurring revenueRevenue expected to repeat under subscriptions, contracts, renewals, or recurring customer usage.View full glossary entry thesis.
Advisor Disagreement
What do our AI Advisors disagree about most? The primary disagreement across the reports centers on the long-term viability of the company's infrastructure pivot. Some perspectives argue that the massive capital expenditurescapital expenditureCapital expenditure (CAPEX) is spending on long-lived assets or major improvements expected to support operations over multiple periods.View full glossary entry and international acquisitions represent a visionary transition toward a vertically integrated, global platform with a durable physical moat. Conversely, other views interpret these moves as defensive, value-destroying empire-building designed to mask organic domestic stagnation. There is also disagreement regarding the stickiness of the subscriber base when transitioning from heavily discounted compounded drugs to expensive branded alternatives.
Base-Case Forces
Near-certain positive forces
Top Drivers / Tailwinds
Near-certain forces that support the investment thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Driver / Tailwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| Core Biological Demand Anchoring | Sector And Industry | +12% | +15% | The core legacy business in men's and women's health, such as hair loss and sexual health, remains highly recurring. This segment addresses deeply anchored biological imperatives, making demand highly resilient during macroeconomic downturns. The subscription nature of these treatments provides a stable, high-margin revenue floor that helps subsidize newer, lower-margin initiatives, ensuring baseline operational stability. |
| International Footprint Expansion | Competitive Positioning | +10% | +10% | Recent international acquisitions provide an immediate geographic footprint across Europe and the Asia-Pacific region. This expansion allows the company to diversify its regulatory exposure and leverage its digital front-door architecture across a broader total addressable markettotal addressable marketTotal addressable market (TAM) is the full revenue opportunity available if a product or service achieved complete adoption within its relevant market.View full glossary entry, potentially capturing economies of scaleeconomies of scaleCost advantages gained by increasing production volume and optimizing manufacturing processes.View full glossary entry and driving long-term international growth that offsets domestic deceleration. |
| Personalized Formulation Shift | Innovation And Product | +8.0% | +10% | The company is increasingly focusing on personalized, multi-ingredient dosages and compounded formulations. By combining multiple active ingredients into proprietary formats, the platform creates synthetic switching costsswitching costsFinancial, operational, technical, contractual, or learning costs incurred when changing products or providers.View full glossary entry and a localized moat, helping defend gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry against pure generic competition and establishing a unique value proposition that enhances customer retention over the forecast horizon. |
| Domestic Supply Chain Reshoringsupply chain reshoringSupply chain reshoring is the relocation of production or sourcing closer to domestic markets to improve resilience, control, or policy alignment.View full glossary entry | Regulatory | +5.0% | +5.0% | Investments in domestic compounding facilities align with federal incentives rewarding domestic pharmaceutical manufacturing. This domestic footprint provides a strategic asset, potentially yielding regulatory shields or tax subsidies while ensuring supply chainsupply chainThe network of suppliers, producers, logistics providers, distributors, and customers involved in creating and delivering a product or service.View full glossary entry resilience during global trade frictions, thereby protecting the company from foreign generic dumping and supply disruptions. |
Near-certain negative forces
Top Frictions / Headwinds
Near-certain forces that could slow, cap, or damage the thesis. These forces are treated as part of the base case (more than 60% probability of occurrence). Impact columns are specific to this asset class.
Scroll to view all columns
| Friction / Headwind | Category | Est. stock-price impact | Est. earnings impact | Why it matters |
|---|---|---|---|---|
| GLP-1glp 1Glucagon-like peptide-1 (GLP-1) is a hormone involved in glucose regulation, insulin response, digestion, and appetite.View full glossary entry Compounding Regulatory Cliff | Regulatory | -40% | -45% | The resolution of branded drug shortages and tightening regulatory oversight forcibly close the compounding loophole that fueled recent hyper-growth. Transitioning patients to branded alternatives structurally destroys gross marginsgross marginsThe percentage of revenue remaining after deducting the direct costs of producing goods sold.View full glossary entry and severely limits the addressable marketaddressable marketAddressable market is the portion of the broader market that a business can realistically target with its offering, geography, and distribution.View full glossary entry of cash-pay consumers, as most subscribers are highly sensitive to the massive price hikes associated with patented medications. |
| Structural Margin Degradation | Operational Efficiency | -30% | -35% | Shifting from vertically integrated compounding to reselling branded pharmaceuticals permanently impairs unit economicsunit economicsRevenue, variable cost, contribution profit, and acquisition or retention economics measured for one customer, product, transaction, or operating unit.View full glossary entry. The company loses its pricing powerpricing powerThe ability of a company to raise prices without losing significant customer demand.View full glossary entry and becomes a commoditized distributor of third-party intellectual propertyintellectual propertyLegally protected intangible creations such as patents, copyrights, trademarks, designs, trade secrets, and proprietary know-how.View full glossary entry, guaranteeing sustained gross margin compressiongross margin compressionReduction in profitability due to rising input costs and supply chain expenses.View full glossary entry and lower return on invested capitalreturn on invested capitalReturn on invested capital (ROIC) measures how efficiently a business generates after-tax operating profit from the capital invested in its operations.View full glossary entry, which ultimately breaks the thesis that the platform deserves a high-growth technology multipletechnology multipleA valuation ratio applied to a technology business, commonly reflecting expected growth, scalability, margins, and risk.View full glossary entry. |
| Customer Acquisition Costcustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry Inflation | Competitive Positioning | -20% | -25% | Customer acquisition costscustomer acquisition costsThe sales and marketing cost required to acquire a new customer.View full glossary entry are rising exponentially due to search engine disintermediation, AI-driven search agents, and aggressive competition from deep-pocketed players. This competitive density bids up advertising rates, structurally compressing operating leverageoperating leverageThe sensitivity of operating profit to changes in revenue caused by the mix of fixed and variable costs.View full glossary entry and making it increasingly difficult for the platform to maintain its historical customer lifetime value metrics without unsustainable marketing expenditures. |
| Debt-Funded M&A and Leverage Overhang | Capital Allocation | -20% | -20% | The rapid accumulation of debt and convertible notes to fund international acquisitions introduces severe balance sheetbalance sheetA financial statement showing assets, liabilities, and equity at a specific point in time.View full glossary entry fragility. Servicing this leverage in a higher-for-longer interest rate environment will heavily consume free cash flowfree cash flowFree cash flow (FCF) is cash generated after operating expenses and capital expenditures that remains available for debt reduction, reinvestment, or shareholder returns.View full glossary entry and limit strategic optionality, leaving the company highly vulnerable to refinancing risks if organic cash generation continues to deteriorate. |
What Could Break or Accelerate the Thesis
Plausible downside scenarios
Tail Risks
Tail yet plausible downside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Complete FDA Compounding Ban | 40% | -45% | Regulatory | The FDA could issue a blanket prohibition or intense crackdown on compounded peptides and other personalized formulations. This would instantly nuke the company's highest-growth segments, triggering massive subscriber churn, class-action lawsuits over marketing claims, and catastrophic write-downs of newly built physical compounding infrastructure. |
| Debt Refinancingdebt refinancingReplacing existing debt with new borrowing, often to change maturity, interest cost, currency, or covenants.View full glossary entry and Liquidity Crisisliquidity crisisA condition in which an institution or market cannot obtain cash or funding needed to meet near-term obligations without severe losses.View full glossary entry | 30% | -40% | Macroeconomic And Macrofinancial | If structural unprofitability persists and cash burncash burnThe rate at which a company consumes its cash reserves to fund operations before achieving profitability.View full glossary entry accelerates, the heavy debt loaddebt loadSignificant financial burden requiring constant cash flow to maintain solvency and service interest.View full glossary entry could trigger covenant breaches. In a tight-liquidity environment, the company would face punitive refinancing terms or highly dilutive equity raisesdilutive equity raisesIssuing new shares to fund operations, which reduces the ownership percentage of existing shareholders.View full glossary entry, severely impairing shareholder value and potentially leading to a distressed restructuring of the capital structurecapital structureThe mix of debt and equity used to finance a business.View full glossary entry. |
Plausible upside scenarios
Tail Opportunities
Tail yet plausible upside scenarios selected for their highest potential impact.
Scroll to view all columns
| Tail scenario | Chance of Occurring | Stock Price Impact | Exposure category | Why plausible / what changes |
|---|---|---|---|---|
| Strategic Acquisition by Healthcare or Tech Major | 25% | +35% | Competitive Positioning | As the valuation multiplevaluation multipleA ratio comparing market or enterprise value with a financial measure such as earnings, revenue, book value, or cash flow.View full glossary entry compresses, the company's active subscriber base and digital front-door infrastructure could make it an attractive acquisition target for legacy pharmacy chains, insurers, or tech giants looking for a turnkey direct-to-consumer health platform, providing a sudden premium buyout exit for shareholders. |
| Proprietary AI Diagnostic Platform Launch | 15% | +35% | Innovation And Product | Successfully commercializing a proprietary, regulatory-approved AI diagnostic and triage platform could allow the company to transition from a low-margin distributor to a high-margin software provider, radically resetting operating efficiency, lowering provider costs to near zero, and rebuilding a highly defensible technological moattechnological moatA durable competitive advantage created by proprietary technology, know-how, data, patents, engineering capability, or technical scale.View full glossary entry. |
Company Financial Analysis
Hims & Hers Health Earnings and Financials Analysis by AI
Financial figures available as of Jul 05, 2026. Only filings and source records available by this analysis date are included.
Earnings and financials
The company's financial health is showing major warning signs after a period of rapid growth. While 2025 was highly profitable with strong revenue growth, the first quarter of 2026 revealed a severe reversal, with growth slowing to single digits and the company posting a massive net loss of ninety-two million dollars. Most assessments agree that the highly profitable days of selling custom weight-loss drugs are ending, and the shift to selling lower-margin brand-name drugs will permanently hurt earnings. However, there is disagreement on the future outlook. Some believe the company can recover its profitability by 2028 as it scales its new business, while others argue that the earnings power is structurally broken and the company will continue to burn cash due to high customer acquisition costs.
Revenue, earnings, and cash flow
The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | USD 2.3B | USD 128.4M | USD 74M |
| 2024 | USD 1.5B | USD 126M | USD 198.3M |
| 2023 | USD 872M | USD -23.5M | USD 47M |
| 2022 | USD 526.9M | USD -65.7M | USD -33.8M |
| 2021 | USD 271.9M | USD -107.7M | USD -39.4M |
Valuation context: historical P/E
The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.
| Fiscal year | P/E | Earnings basis | Currency basis | Ticker / reporting |
|---|---|---|---|---|
| 2025 | 62.8x | TTM | Native | USD / USD |
| 2024 | 46.2x | TTM | Native | USD / USD |
| 2023 | -- | TTM | Loss-making | USD / USD |
| 2022 | -- | Annual | Loss-making | USD / USD |
| 2021 | -- | Annual | Loss-making | USD / USD |
P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.
Profitability and margins
Profit margins are facing a structural collapse. Historically, the company enjoyed exceptionally high gross margins of around eighty percent by selling custom-compounded drugs. However, gross margins have plummeted to sixty-five percent and operating margins have swung deep into the red. Most assessments agree that this margin compression is permanent, driven by the forced transition to reselling lower-margin brand-name drugs and skyrocketing customer acquisition costs. Opinions clash on the future trajectory. Bullish views suggest that margins will stabilize and eventually expand as marketing costs normalize and automated systems take over. Bearish views argue that without a unique product, the company will be forced to compete on price against massive retail giants, permanently dragging margins down to traditional retail pharmacy levels and destroying the justification for its high valuation.
The table compares up to five fiscal years of operating income and reported profitability margins.
| Fiscal year | Operating income | Operating margin | Net margin |
|---|---|---|---|
| 2025 | USD 105.6M | 4.5% | 5.5% |
| 2024 | USD 61.9M | 4.2% | 8.5% |
| 2023 | USD -29.5M | -3.4% | -2.7% |
| 2022 | USD -68.7M | -13.0% | -12.5% |
| 2021 | USD -115M | -42.3% | -39.6% |
Balance sheet and leverage
The company's balance sheet has deteriorated significantly, moving from a virtually debt-free position to a highly leveraged state. Debt-to-equity ratios have skyrocketed due to massive borrowing and convertible note issuances used to fund international acquisitions. While the company still holds a decent amount of cash, the sudden swing to large net losses in early 2026 threatens to rapidly deplete these reserves. Most assessments agree that this high leverage removes the company's financial safety net and makes it highly vulnerable to high interest rates. However, there is some disagreement: some believe the debt was a calculated risk to build a physical empire before competitors could react, while others view it as a dangerous trap that leaves the company highly exposed to refinancing crises if cash flows do not recover quickly.
The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.
| Fiscal year | Total debt | Cash + short-term investments | Net cash / (debt) | Current ratio |
|---|---|---|---|---|
| 2025 | USD 1.1B | USD 577.5M | USD 892M net debt | 1.90x |
| 2024 | USD 11.3M | USD 300.3M | USD 209.2M net cash | 1.79x |
| 2023 | USD 9.9M | USD 221M | USD 86.7M net cash | 3.00x |
| 2022 | USD 5.3M | USD 179.6M | USD 41.5M net cash | 4.52x |
| 2021 | USD 5.5M | USD 247.3M | USD 66.3M net cash | 3.41x |
Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.
Capex and investment intensity
The company is rapidly shifting from a low-cost online marketing platform to a capital-heavy business. Spending on physical compounding facilities and international acquisitions has surged dramatically. Most assessments agree that this heavy spending is defensive, aimed at securing supply chains and buying international revenue to cover up slowing growth in the United States. However, opinions differ on what this means for the future. Optimistic views suggest that building these physical facilities will create a strong competitive moat and lock in pricing power over the long term. In contrast, cautious views warn that investing heavily in physical infrastructure right as profit margins collapse will severely drag down the company's return on investment and drain its free cash flow, making it a risky bet for long-term shareholders.
The table compares up to five fiscal years of capital expenditure and research-and-development investment.
| Fiscal year | Capital expenditure | R&D spend |
|---|---|---|
| 2025 | USD 226M | USD 149.3M |
| 2024 | USD 52.8M | USD 78.8M |
| 2023 | USD 26.5M | USD 48.2M |
| 2022 | USD 7.2M | USD 29.2M |
| 2021 | USD 5M | USD 22.4M |
Quarterly Forecast Scenarios
Hims & Hers Health Quarterly Forecast Scenarios
One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.
Scroll to view all columns
| Timeline | Bear Case Stock Price (USD) | Base Case Stock Price (USD) | Bull Case Stock Price (USD) | S&P 500 benchmark (USD) |
|---|---|---|---|---|
| $29.44 | $30.97 | $33.86 | $736.09 | |
| $25.02 | $27.49 | $35.55 | $724.14 | |
| $21.27 | $25.30 | $38.39 | $713.57 | |
| $19.14 | $23.32 | $36.86 | $723.38 | |
| $17.61 | $22.52 | $40.54 | $716.61 | |
| $17.61 | $22.31 | $45.41 | $738.34 | |
| $17.75 | $22.50 | $49.04 | $746.91 | |
| $15.98 | $22.98 | $56.40 | $771.93 | |
| $15.18 | $22.71 | $53.58 | $782.73 | |
| $14.57 | $23.42 | $58.93 | $807.31 | |
| $15.01 | $24.15 | $63.65 | $822.72 | |
| $15.70 | $24.89 | $71.29 | $846.10 | |
| $15.39 | $25.37 | $75.56 | $852.53 | |
| $15.85 | $25.16 | $72.54 | $882.91 | |
| $15.38 | $25.86 | $78.34 | $900.46 | |
| $15.07 | $26.44 | $83.83 | $922.67 | |
| $14.77 | $27.05 | $90.54 | $935.91 | |
| $15.06 | $27.25 | $87.82 | $952.30 | |
| $14.76 | $27.96 | $93.09 | $976.28 | |
| $14.47 | $28.56 | $97.74 | $1,002 |
Research Provenance
References & Context
This Hims & Hers Health consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.
Primary analysis inputs
- iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
- iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
- Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
- Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Independent AI Advisor panel
- AI Advisors
- 12
- AI Researchers
- 7
- AI Thinkers
- 5
Context retained with this Consensus
The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.
Global context snapshot
2025 Full-Year Global Market and World-Events Context
Download Archived SnapshotCoverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31
- File size
- 90.8K bytes
- Words
- 12.8K words
- Characters
- 90.8K characters
This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.
The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| DeepSeek shock and AI economics reset | 2025-01-27 | OPEN ENDED TREND |
| US tariff regime escalation and trade-system rupture | 2025-02-01 | ACTIVE POLICY REGIME |
| Federal Reserve easing cycle after a prolonged hold | 2025-09-17 | ACTIVE POLICY REGIME |
Representative Sources of the Context File
And more sources from the retained context package.
2026 Year-to-Date Global Market Context through 2026-05-31
Download Archived SnapshotCoverage 2026-01-01 to 2026-05-31 · Knowledge cutoff 2026-05-31
- File size
- 78K bytes
- Words
- 10.9K words
- Characters
- 78K characters
This year-to-date package described the geopolitical, macroeconomic, monetary-policy, technology, trade, energy, and cross-asset developments available through the batch knowledge cutoff of 2026-05-31.
It supplied dated market and policy context, including rates, sovereign yields, equities, foreign exchange, energy, metals, and digital assets, for the forecast generation workflow.
| Top 3 Market Shifts From File | Date | Status |
|---|---|---|
| The Iran and Strait of Hormuz conflict shocked energy markets | 2026-02-28 | STARTED AND ONGOING |
| U.S. monetary policy entered the Warsh transition | 2026-01-30 | STARTED AND ACTIVE POLICY TRANSITION |
| Agentic AI and infrastructure spending kept expanding | 2026-01-01 | OPEN ENDED |
Representative Sources of the Context File
And more sources from the retained context package.
Fundamental context
Income statement
34 fieldscostOfRevenue · currency_symbol · date · depreciationAndAmortization · +30 more fields
Balance sheet
64 fieldsaccountsPayable · accumulatedAmortization · accumulatedDepreciation · accumulatedOtherComprehensiveIncome · +60 more fields
Cash flow
32 fieldsbeginPeriodCashFlow · capitalExpenditures · cashAndCashEquivalentsChanges · cashFlowsOtherOperating · +28 more fields
Outstanding shares
4 fieldsdate · dateFormatted · shares · sharesMln
annual: 2020-12-31–2026-01-01, 12 periods; quarterly: 2023-06-30–2026-03-31, 12 periods
Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).